NC-TANNER-PHARMA-GROUP
25.3.2020 07:32:10 CET | Business Wire | Press release
Tanner Pharma Group today announced they are expanding their program by which the company provides access to LEUKINE® (sargramostim) in international markets. LEUKINE®, approved by the US FDA in 1991 and now manufactured by Partner Therapeutics, is a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) that stimulates the immune system and has been used in leukemia patients to reduce the risk of infection.
On March 23, 2020, Partner Therapeutics announced that Leukine® is being assessed in the SARPAC trial (sar gramostim in p atients with a cute hypoxic respiratory failure due to C OVID-19 – EudraCT #2020-001254-22) at University Hospital Ghent, Belgium to treat patients with respiratory illness associated with COVID-19.
“The collaboration we have had with Tanner Pharma Group has given us a regulatory-compliant pathway to make LEUKINE available in international markets,” said Bob Mulroy, CEO of Partner Therapeutics. “The expansion of this partnership makes Tanner our designated program manager and creates a shared objective to more effectively provide access to more patients in need.”
If a patient is located in a country where Leukine is not available commercially and has a life-threatening illness whereby survival could potentially be prolonged in a clinically meaningful way, physicians may be able to have Leukine imported for their patients through named patient supply via the LEUKINE EMERGENCY ACCESS PROGRAM (LEAP) managed by Tanner.
“Leukine has been an important part of the treatment regimen for various diseases over the past thirty years; now, there is an even greater possible need as demonstrated by initiation of the clinical trial in Belgium,” said Banks Bourne, CEO of Tanner Pharma Group. “Tanner has been managing this access program for Leukine since May of 2018 and we are ready for this new, very important phase. Our team is incredibly honored to be trusted with the expansion of this collaboration, and we are mobilized to help patients around the world to make a positive impact.”
For more information about this program or to request access to LEUKINE®:
Telephone: +1 704 643 8989
Email: leukine@tannerpharma.com
About LEUKINE® (sargramostim)
Leukine® is a yeast-derived recombinant humanized granulocyte-macrophage colony stimulating factor (rhuGM-CSF) and the only FDA approved GM-CSF. GM-CSF is an important leukocyte growth factor known to play a key role in hematopoiesis, epithelial repair, and augmentation of innate host defense by effecting the growth and maturation of multiple cell lineages as well as the functional activities of these cells in antigen presentation and cell mediated immunity.
About Tanner Pharma Group
Tanner Pharma Group partners with biopharmaceutical companies to provide turn-key commercialization solutions to increase patient access to medicines around the world. With an unparalleled blend of local market knowledge, international supply chain expertise across more than 130 countries, and high regulatory compliance and quality standards, it provides tailored solutions to biopharmaceutical companies outside their core markets of focus. For more information, visit www.tannerpharma.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200324005848/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpenGate Capital Signs Definitive Agreement to Acquire Total Safety’s Europe and Middle East Division29.4.2026 09:00:00 CEST | Press release
OpenGate Capital (“OpenGate”), a global private equity firm, announced today that it has signed a definitive agreement to acquire the European and the Middle Eastern (“EMEA”) division of Total Safety, a Littlejohn & Co. portfolio company. Total Safety EMEA is a leading provider of mission-critical safety and compliance solutions serving petrochemical and oil & gas customers across EMEA. The company focuses on workforce protection and regulatory compliance in complex, safety critical environments. Terms of the acquisition were not disclosed. Headquartered in Diepenbeek, Belgium, Total Safety EMEA offers a fully integrated, one-stop platform spanning safety services, rental equipment and product sales. Services include the deployment of highly trained personnel for critical safety operations, short- and long-term rental of essential equipment and the supply of personal protective equipment. As a trusted partner embedded in highly regulated environments, Total Safety EMEA supports clients
AI-driven Bot Attacks Surged 12.5x According to Thales Bad Bot Report29.4.2026 09:00:00 CEST | Press release
AI-driven automation is accelerating machine activity online as bots outpace humans and redefine how the internet operates Bots now dominate the internet, accounting for over half of all traffic, with 40% classified as malicious. AI is erasing the line between legitimate and malicious activity, making intent - not identity - the new security challenge. APIs and identity systems are primary targets, with attackers bypassing front-end defenses to exploit core business logic at scale. Thales today released the 2026 Bad Bot Report: Bad Bots in the Agentic Age, revealing a fundamental shift in how the internet operates, as AI-accelerated automation becomes a defining feature of modern digital infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428783532/en/ ©Thales The findings highlight three major structural changes: the emergence of AI agents as a new category of internet traffic, the dominance of automated activ
Hytera to Host Global Partner Summit 2026 in Shanghai,Advancing AI-Powered Mission-Critical Communications29.4.2026 08:00:00 CEST | Press release
Hytera Communications, a leading global provider of critical communications technologies and solutions, today announced it will host its highly anticipated Hytera Global Partner Summit (HGPS) 2026 in Shanghai on May 8, 2026, bringing together partners from more than 60 countries worldwide. Held under the theme "Advancing Together", this year’s summit marks the return of HGPS to China after several years overseas. As Hytera’s flagship event, it serves as a key platform to deepen collaboration, align strategic priorities, and unlock new opportunities for shared growth in an increasingly dynamic global market. The agenda will feature executive keynotes, new product launches, technology workshops, and partner-focused discussions, offering participants valuable insights into market trends and future development directions. A major highlight of HGPS 2026 will be the immersive exhibition pavilion, showcasing Hytera’s end-to-end portfolio and next-generation AI-powered solutions. Spanning sect
Autonomous University of Sinaloa (UAS) Releases Study on the Positive Economic Impacts of Pacifico Mexinol Project in Northern Sinaloa29.4.2026 00:39:00 CEST | Press release
The study, among other factors, estimates for every one job created by Pacifico Mexinol, eight additional jobs on average are created across the broader economy, and Mexico’s GDP will rise by over $2b USD during construction. The study is the first economic impact study of its kind at a state level in Mexico and the methodology can be replicated globally across other sectors and regions. As part of an ongoing joint effort between the academic and commercial sectors, stemming from a Collaboration Agreement between the Autonomous University of Sinaloa (UAS) and Pacifico Mexinol (a subsidiary of Transition Industries) signed in 2024, UAS released the findings of the economic effects study of the world's largest ultra-low-carbon methanol plant, located near Topolobampo, Ahome, Sinaloa. The Pacifico Mexinol project is aligned with the UN Sustainable Development Goals by promoting the use of clean energy, the utilization of treated wastewater, and climate change mitigation. It protects local
Suzano 2025 Annual Report on Form 20-F28.4.2026 23:32:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2025 Annual Report on Form 20-F was filed on March 24, 2026 with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20260428152792/en/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom